Discovery of circulating miRNAs as biomarkers of chronic Chagas heart disease via a small RNA-Seq approach.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 Jan 2024
12 Jan 2024
Historique:
received:
20
09
2023
accepted:
05
01
2024
medline:
13
1
2024
pubmed:
13
1
2024
entrez:
12
1
2024
Statut:
epublish
Résumé
Chagas disease affects approximately 7 million people worldwide in Latin America and is a neglected tropical disease. Twenty to thirty percent of chronically infected patients develop chronic Chagas cardiomyopathy decades after acute infection. Identifying biomarkers of Chagas disease progression is necessary to develop better therapeutic and preventive strategies. Circulating microRNAs are increasingly reliable biomarkers of disease and therapeutic targets. To identify new circulating microRNAs for Chagas disease, we performed exploratory small RNA sequencing from the plasma of patients and performed de novo miRNA prediction, identifying potential new microRNAs. The levels of the new microRNAs temporarily named miR-Contig-1519 and miR-Contig-3244 and microRNAs that are biomarkers for nonchagasic cardiomyopathies, such as miR-148a-3p and miR-224-5p, were validated by quantitative reverse transcription. We found a specific circulating microRNA signature defined by low miR-Contig-3244, miR-Contig-1519, and miR-148a-3 levels but high miR-224-5p levels for patients with chronic Chagas disease. Finally, we predicted in silico that these altered circulating microRNAs could affect the expression of target genes involved in different cellular pathways and biological processes, which we will explore in the future.
Identifiants
pubmed: 38216639
doi: 10.1038/s41598-024-51487-9
pii: 10.1038/s41598-024-51487-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1187Subventions
Organisme : Agencia Nacional e Promoción Científica y Tecnológica
ID : PICT 2013-1892
Organisme : Secretaría de Ciencia y Tecnología, Universidad Nacional de Rosario
ID : 1MED410
Organisme : Ministerio de Economía y competitividad and Fondo Europeo de Desarrollo Regional
ID : SAF2016-75988-R (MINECO/FEDER)
Organisme : Ministerio de Economía y competitividad and Fondo Europeo de Desarrollo Regional
ID : SAF2015-63868-R (MINECO/FEDER)
Organisme : Red de Investigación de Centros de Enfermedades Tropicales
ID : RICET RD12/0018/0004
Organisme : Consejería de Sanidad, Comunidad de Madrid
ID : S-2010/BMD-2332
Organisme : Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación and Fondo Europeo de Desarrollo Regional
ID : PGC2018-096132-B-I00
Informations de copyright
© 2024. The Author(s).
Références
Pérez-Molina, J. A. & Molina, I. Chagas disease. Lancet 391, 82–94 (2018).
pubmed: 28673423
doi: 10.1016/S0140-6736(17)31612-4
Prata, A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect. Dis. 1, 92–100 (2001).
pubmed: 11871482
doi: 10.1016/S1473-3099(01)00065-2
Rassi, A., Rassi, A. & Marin-Neto, J. A. Chagas disease. Lancet 375, 1388–1402 (2010).
pubmed: 20399979
doi: 10.1016/S0140-6736(10)60061-X
Blondal, T. et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 59, S1-6 (2013).
pubmed: 23036329
doi: 10.1016/j.ymeth.2012.09.015
Laugier, L. et al. miRNAs may play a major role in the control of gene expression in key pathobiological processes in Chagas disease cardiomyopathy. PLoS Negl. Trop. Dis. 14, e0008889 (2020).
pubmed: 33351798
pmcid: 7787679
doi: 10.1371/journal.pntd.0008889
Murchison, E. P. & Hannon, G. J. miRNAs on the move: miRNA biogenesis and the RNAi machinery. Curr. Opin. Cell Biol. 16, 223–229 (2004).
pubmed: 15145345
doi: 10.1016/j.ceb.2004.04.003
Bronze-da-Rocha, E. MicroRNAs expression profiles in cardiovascular diseases. Biomed. Res. Int. 2014, 985408 (2014).
pubmed: 25013816
pmcid: 4075084
doi: 10.1155/2014/985408
de Gonzalo-Calvo, D., Iglesias-Gutiérrez, E. & Llorente-Cortés, V. Epigenetic biomarkers and cardiovascular disease: Circulating MicroRNAs. Rev. Esp. Cardiol. (Engl. Ed.) 70, 763–769 (2017).
pubmed: 28623159
Sayed, D., Hong, C., Chen, I.-Y., Lypowy, J. & Abdellatif, M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ. Res. 100, 416–424 (2007).
pubmed: 17234972
doi: 10.1161/01.RES.0000257913.42552.23
van Empel, V. P. M., De Windt, L. J. & da Costa Martins, P. A. Circulating miRNAs: Reflecting or affecting cardiovascular disease?. Curr. Hypertens. Rep. 14, 498–509 (2012).
pubmed: 22996205
doi: 10.1007/s11906-012-0310-7
van Rooij, E. et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. U.S.A. 105, 13027–13032 (2008).
pubmed: 18723672
pmcid: 2529064
doi: 10.1073/pnas.0805038105
Correia, C. N. et al. Circulating microRNAs as potential biomarkers of infectious disease. Front. Immunol. 8, 118 (2017).
pubmed: 28261201
pmcid: 5311051
doi: 10.3389/fimmu.2017.00118
Miao, C., Chang, J., Zhang, G. & Fang, Y. MicroRNAs in type 1 diabetes: New research progress and potential directions. Biochem. Cell Biol. 96, 498–506 (2018).
pubmed: 29554441
doi: 10.1139/bcb-2018-0027
Lopez-Pedrera, C. et al. Role of microRNAs in the development of cardiovascular disease in systemic autoimmune disorders. Int. J. Mol. Sci. 21, E2012 (2020).
doi: 10.3390/ijms21062012
Jones Buie, J. N., Goodwin, A. J., Cook, J. A., Halushka, P. V. & Fan, H. The role of miRNAs in cardiovascular disease risk factors. Atherosclerosis 254, 271–281 (2016).
pubmed: 27693002
pmcid: 5125538
doi: 10.1016/j.atherosclerosis.2016.09.067
Moldovan, L. et al. Methodological challenges in utilizing miRNAs as circulating biomarkers. J. Cell. Mol. Med. 18, 371–390 (2014).
pubmed: 24533657
pmcid: 3943687
doi: 10.1111/jcmm.12236
Linhares-Lacerda, L. et al. Circulating plasma MicroRNA-208a as potential biomarker of chronic indeterminate phase of Chagas disease. Front. Microbiol. 9, 269 (2018).
pubmed: 29559958
pmcid: 5845676
doi: 10.3389/fmicb.2018.00269
Nonaka, C. K. V. et al. Circulating miRNAs as potential biomarkers associated with cardiac remodeling and fibrosis in chagas disease cardiomyopathy. Int. J. Mol. Sci. 20, E4064 (2019).
doi: 10.3390/ijms20164064
Ferreira, L. R. P. et al. MicroRNAs miR-1, miR-133a, miR-133b, miR-208a and miR-208b are dysregulated in chronic Chagas disease cardiomyopathy. Int. J. Cardiol. 175, 409–417 (2014).
pubmed: 24910366
doi: 10.1016/j.ijcard.2014.05.019
Friedländer, M. R. et al. Discovering microRNAs from deep sequencing data using miRDeep. Nat. Biotechnol. 26, 407–415 (2008).
pubmed: 18392026
doi: 10.1038/nbt1394
O’Brien, J., Hayder, H., Zayed, Y. & Peng, C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front. Endocrinol. https://doi.org/10.3389/fendo.2018.00402 (2018).
doi: 10.3389/fendo.2018.00402
Kuleshov, M. V. et al. Enrichr: A comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90-97 (2016).
pubmed: 27141961
pmcid: 4987924
doi: 10.1093/nar/gkw377
Xie, Z. et al. Gene set knowledge discovery with Enrichr. Curr. Protoc. 1, e90 (2021).
pubmed: 33780170
pmcid: 8152575
doi: 10.1002/cpz1.90
Huang, R. et al. The NCATS BioPlanet—An integrated platform for exploring the universe of cellular signaling pathways for toxicology, systems biology, and chemical genomics. Front. Pharmacol. 10, 445 (2019).
pubmed: 31133849
pmcid: 6524730
doi: 10.3389/fphar.2019.00445
Gao, W. et al. Multiplex indexing approach for the detection of DNase I hypersensitive sites in single cells. Nucleic Acids Res. 49, e56 (2021).
pubmed: 33693880
pmcid: 8191781
doi: 10.1093/nar/gkab102
Patel, V. et al. The stretch responsive microRNA miR-148a-3p is a novel repressor of IKBKB, NF-κB signaling, and inflammatory gene expression in human aortic valve cells. FASEB J. 29, 1859–1868 (2015).
pubmed: 25630970
pmcid: 4771066
doi: 10.1096/fj.14-257808
Wang, F. et al. KLF5/LINC00346/miR-148a-3p axis regulates inflammation and endothelial cell injury in atherosclerosis. Int. J. Mol. Med. 48, 1–10 (2021).
doi: 10.3892/ijmm.2021.4985
Giri, B. R. & Cheng, G. Host miR-148 regulates a macrophage-mediated immune response during Schistosoma japonicum infection. Int. J. Parasitol. 49, 993–997 (2019).
pubmed: 31726056
doi: 10.1016/j.ijpara.2019.08.002
Aoki, M. P. et al. Cruzipain, a major Trypanosoma cruzi antigen, promotes arginase-2 expression and survival of neonatal mouse cardiomyocytes. Am. J. Physiol. Cell Physiol. 286, C206-212 (2004).
pubmed: 13679306
doi: 10.1152/ajpcell.00282.2003
Huang, F. et al. miR-148a-3p mediates notch signaling to promote the differentiation and M1 activation of macrophages. Front. Immunol. 8, 1327 (2017).
pubmed: 29085372
pmcid: 5650608
doi: 10.3389/fimmu.2017.01327
Cheng, Y. et al. Inhibition of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 attenuates high glucose-induced cardiomyocyte apoptosis via regulation of miR-181a-5p. Exp. Anim. 69, 34–44 (2020).
pubmed: 31353329
doi: 10.1538/expanim.19-0058
Zhai, C. et al. LncRNA AK087124/miR-224-5p/PTEN axis modulates endothelial cell injury in atherosclerosis through apoptosis and AKT signaling pathway. Arch. Biochem. Biophys. 705, 108916 (2021).
pubmed: 33974917
doi: 10.1016/j.abb.2021.108916
Zheng, H., Shi, L., Tong, C., Liu, Y. & Hou, M. circSnx12 is involved in ferroptosis during heart failure by targeting miR-224-5p. Front. Cardiovasc. Med. 8, 656093 (2021).
pubmed: 33969020
pmcid: 8097164
doi: 10.3389/fcvm.2021.656093
Levstek, T., Karun, T., Rehberger Likozar, A., Šebeštjen, M. & Trebušak Podkrajšek, K. Interplay between microRNAs, serum proprotein convertase subtilisin/kexin type 9 (PCSK9), and lipid parameters in patients with very high lipoprotein(a) treated with PCSK9 inhibitors. Genes (Basel) 14, 632 (2023).
pubmed: 36980904
doi: 10.3390/genes14030632
James, K. et al. Increased expression of miR-224-5p in circulating extracellular vesicles of patients with reduced coronary flow reserve. BMC Cardiovasc. Disord. 22, 321 (2022).
pubmed: 35850658
pmcid: 9290204
doi: 10.1186/s12872-022-02756-w
Nakao, A. et al. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 16, 5353–5362 (1997).
pubmed: 9311995
pmcid: 1170167
doi: 10.1093/emboj/16.17.5353
Ferreira, R. R. et al. The search for biomarkers and treatments in Chagas disease: Insights from TGF-beta studies and immunogenetics. Front. Cell. Infect. Microbiol. 11, 767576 (2021).
pubmed: 35186778
doi: 10.3389/fcimb.2021.767576
Waghabi, M. C. et al. Transforming growth factor-ß as a therapeutic target for the cardiac damage of Chagas disease. Mem. Inst. Oswaldo Cruz 117, e210395 (2022).
pubmed: 35239842
pmcid: 8896758
doi: 10.1590/0074-02760210395
Ferreira, R. R. et al. In Chagas disease, transforming growth factor beta neutralization reduces Trypanosoma cruzi infection and improves cardiac performance. Front. Cell. Infect. Microbiol. 12, 1017040 (2022).
pubmed: 36530434
pmcid: 9748701
doi: 10.3389/fcimb.2022.1017040
Ferragut, F., Acevedo, G. R. & Gómez, K. A. T cell specificity: A great challenge in Chagas disease. Front. Immunol. 12, 674078 (2021).
pubmed: 34267750
pmcid: 8276045
doi: 10.3389/fimmu.2021.674078
Acevedo, G. R., Girard, M. C. & Gómez, K. A. The unsolved Jigsaw puzzle of the immune response in Chagas disease. Front. Immunol. 9, 1929 (2018).
pubmed: 30197647
pmcid: 6117404
doi: 10.3389/fimmu.2018.01929
Cuervo, H. et al. Inducible nitric oxide synthase and arginase expression in heart tissue during acute Trypanosoma cruzi infection in mice: Arginase I is expressed in infiltrating CD68+ macrophages. J. Infect. Dis. 197, 1772–1782 (2008).
pubmed: 18473687
doi: 10.1086/529527
Poveda, C. et al. Interaction of signaling lymphocytic activation molecule family 1 (SLAMF1) receptor with Trypanosoma cruzi is strain-dependent and affects NADPH oxidase expression and activity. PLoS Negl. Trop. Dis. 14, e0008608 (2020).
pubmed: 32925918
pmcid: 7515593
doi: 10.1371/journal.pntd.0008608
Barrias, E., Reignault, L., de Carvalho, T. M. U. & de Souza, W. Clathrin coated pit dependent pathway for Trypanosoma cruzi internalization into host cells. Acta Trop. 199, 105057 (2019).
pubmed: 31202818
doi: 10.1016/j.actatropica.2019.105057
Chuenkova, M. V. & Pereira, M. A. The T. Cruzi trans-sialidase induces PC12 cell differentiation via MAPK/ERK pathway. Neuroreport 12, 3715–3718 (2001).
pubmed: 11726780
doi: 10.1097/00001756-200112040-00022
Lattanzi, R., Maftei, D., Fullone, M. R. & Miele, R. Trypanosoma cruzi trans-sialidase induces STAT3 and ERK activation by prokineticin receptor 2 binding. Cell Biochem. Funct. 39, 326–334 (2021).
pubmed: 32892338
doi: 10.1002/cbf.3586
Ferri, G., Musikant, D. & Edreira, M. M. Host cell Rap1b mediates cAMP-dependent invasion by Trypanosoma cruzi. PLoS Negl. Trop. Dis. 17, e0011191 (2023).
pubmed: 36897926
pmcid: 10032529
doi: 10.1371/journal.pntd.0011191
Mukherjee, S. et al. Trypanosoma cruzi infection activates extracellular signal-regulated kinase in cultured endothelial and smooth muscle cells. Infect. Immun. 72, 5274–5282 (2004).
pubmed: 15322023
pmcid: 517449
doi: 10.1128/IAI.72.9.5274-5282.2004
Ballinas-Verdugo, M. A. et al. Circulating miR-146a as a possible candidate biomarker in the indeterminate phase of Chagas disease. Biol. Res. 54, 21 (2021).
pubmed: 34289913
pmcid: 8293491
doi: 10.1186/s40659-021-00345-3
Jha, B. K. et al. MicroRNA-155 deficiency exacerbates Trypanosoma cruzi infection. Infect. Immun. https://doi.org/10.1128/IAI.00948-19 (2020).
doi: 10.1128/IAI.00948-19
pubmed: 32312766
pmcid: 7309613
Medina, L. et al. Trypanosoma cruzi and Toxoplasma gondii induce a differential MicroRNA profile in human placental explants. Front. Immunol. 11, 595250 (2020).
pubmed: 33240284
pmcid: 7677230
doi: 10.3389/fimmu.2020.595250
Farani, P. S. G., Ferreira, B. I. S., Gibaldi, D., Lannes-Vieira, J. & Moreira, O. C. Modulation of miR-145-5p and miR-146b-5p levels is linked to reduced parasite load in H9C2 Trypanosoma cruzi infected cardiomyoblasts. Sci. Rep. 12, 1436 (2022).
pubmed: 35082354
pmcid: 8791985
doi: 10.1038/s41598-022-05493-4
Gulyaeva, L. F. & Kushlinskiy, N. E. Regulatory mechanisms of microRNA expression. J. Transl. Med. 14, 143 (2016).
pubmed: 27197967
pmcid: 4873990
doi: 10.1186/s12967-016-0893-x
Pizzamiglio, S. et al. A methodological procedure for evaluating the impact of hemolysis on circulating microRNAs. Oncol. Lett. 13, 315–320 (2017).
pubmed: 28123561
doi: 10.3892/ol.2016.5452
Kirschner, M. B. et al. The impact of hemolysis on cell-free microRNA biomarkers. Front. Genet. 4, 94 (2013).
pubmed: 23745127
pmcid: 3663194
A Quick-Reference Tool for Hemolysis Status | Division of Vector-Borne Diseases | NCEZID | CDC. https://www.cdc.gov/ncezid/dvbd/specimensub/hemolysis-palette.html (2023).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8
Friedländer, M. R., Mackowiak, S. D., Li, N., Chen, W. & Rajewsky, N. miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Res. 40, 37–52 (2012).
pubmed: 21911355
doi: 10.1093/nar/gkr688
Chen, Y. & Wang, X. miRDB: An online database for prediction of functional microRNA targets. Nucleic Acids Res. 48, D127–D131 (2020).
pubmed: 31504780
doi: 10.1093/nar/gkz757
Liu, W. & Wang, X. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol. 20, 18 (2019).
pubmed: 30670076
pmcid: 6341724
doi: 10.1186/s13059-019-1629-z